Cerity Partners
AMLX icon

Cerity Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cerity Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-33,365
Closed -$63.4K – 2529
2024
Q2 		$63.4K Buy
+33,365
New +$64.7K ﹤0.01% 2152

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Cerity Partners's AMLX Position: Q3 2024 in Review

Cerity Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 33,365 shares — an estimated $63.4K sold.

Cerity Partners first reported a position in AMLX in Q2 2024 and held it in 1 quarter. The position peaked at $63.4K in Q2 2024. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Cerity Partners reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cerity Partners sold 33,365 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $63.4K.
  • Cerity Partners first reported a position in Amylyx Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Cerity Partners's Amylyx Pharmaceuticals position peaked at $63.4K in Q2 2024.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Cerity Partners's 13F filing for Q3 2024, filed 12 Nov 2024.